These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 33137541)

  • 21. Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.
    Acquaviva J; Smith DL; Sang J; Friedland JC; He S; Sequeira M; Zhang C; Wada Y; Proia DA
    Mol Cancer Ther; 2012 Dec; 11(12):2633-43. PubMed ID: 23012248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
    Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
    Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC.
    Dompe N; Klijn C; Watson SA; Leng K; Port J; Cuellar T; Watanabe C; Haley B; Neve R; Evangelista M; Stokoe D
    PLoS One; 2018; 13(6):e0199264. PubMed ID: 29912950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in non-small cell lung cancer cells.
    Moran DM; Trusk PB; Pry K; Paz K; Sidransky D; Bacus SS
    Mol Cancer Ther; 2014 Jun; 13(6):1611-24. PubMed ID: 24688052
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells.
    Della Corte CM; Ciaramella V; Di Mauro C; Castellone MD; Papaccio F; Fasano M; Sasso FC; Martinelli E; Troiani T; De Vita F; Orditura M; Bianco R; Ciardiello F; Morgillo F
    Oncotarget; 2016 Jan; 7(4):4265-78. PubMed ID: 26673006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachone.
    Chakrabarti G; Moore ZR; Luo X; Ilcheva M; Ali A; Padanad M; Zhou Y; Xie Y; Burma S; Scaglioni PP; Cantley LC; DeBerardinis RJ; Kimmelman AC; Lyssiotis CA; Boothman DA
    Cancer Metab; 2015; 3():12. PubMed ID: 26462257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer.
    Park KS; Yang H; Choi J; Seo S; Kim D; Lee CH; Jeon H; Kim SW; Lee DH
    Cancer Lett; 2017 Oct; 406():47-53. PubMed ID: 28797845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
    Takezawa K; Okamoto I; Yonesaka K; Hatashita E; Yamada Y; Fukuoka M; Nakagawa K
    Cancer Res; 2009 Aug; 69(16):6515-21. PubMed ID: 19638574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.
    Lee MS; Helms TL; Feng N; Gay J; Chang QE; Tian F; Wu JY; Toniatti C; Heffernan TP; Powis G; Kwong LN; Kopetz S
    Oncotarget; 2016 Jun; 7(26):39595-39608. PubMed ID: 27167191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy.
    Xu K; Park D; Magis AT; Zhang J; Zhou W; Sica GL; Ramalingam SS; Curran WJ; Deng X
    Mol Cancer; 2019 Apr; 18(1):85. PubMed ID: 30971271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selumetinib for the treatment of non-small cell lung cancer.
    Casaluce F; Sgambato A; Maione P; Sacco PC; Santabarbara G; Gridelli C
    Expert Opin Investig Drugs; 2017 Aug; 26(8):973-984. PubMed ID: 28675058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.
    Poon E; Mullins S; Watkins A; Williams GS; Koopmann JO; Di Genova G; Cumberbatch M; Veldman-Jones M; Grosskurth SE; Sah V; Schuller A; Reimer C; Dovedi SJ; Smith PD; Stewart R; Wilkinson RW
    J Immunother Cancer; 2017 Aug; 5(1):63. PubMed ID: 28807001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach.
    Caiola E; Falcetta F; Giordano S; Marabese M; Garassino MC; Broggini M; Pastorelli R; Brunelli L
    J Exp Clin Cancer Res; 2018 Dec; 37(1):302. PubMed ID: 30514331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic Alterations Caused by KRAS Mutations in Colorectal Cancer Contribute to Cell Adaptation to Glutamine Depletion by Upregulation of Asparagine Synthetase.
    Toda K; Kawada K; Iwamoto M; Inamoto S; Sasazuki T; Shirasawa S; Hasegawa S; Sakai Y
    Neoplasia; 2016 Nov; 18(11):654-665. PubMed ID: 27764698
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in
    Feng J; Lian Z; Xia X; Lu Y; Hu K; Zhang Y; Liu Y; Hu L; Yuan K; Sun Z; Pang X
    Acta Pharm Sin B; 2023 Mar; 13(3):1145-1163. PubMed ID: 36970205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergy of WEE1 and mTOR Inhibition in Mutant
    Hai J; Liu S; Bufe L; Do K; Chen T; Wang X; Ng C; Li S; Tsao MS; Shapiro GI; Wong KK
    Clin Cancer Res; 2017 Nov; 23(22):6993-7005. PubMed ID: 28821559
    [No Abstract]   [Full Text] [Related]  

  • 37. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
    Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
    Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deregulation of a Network of mRNA and miRNA Genes Reveals That CK2 and MEK Inhibitors May Synergize to Induce Apoptosis KRAS-Active NSCLC.
    Gober MK; Flight RM; Lambert J; Moseley H; Stromberg A; Black EP
    Cancer Inform; 2019; 18():1176935119843507. PubMed ID: 31105425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer.
    Metro G; Chiari R; Baldi A; De Angelis V; Minotti V; Crinò L
    Future Oncol; 2013 Feb; 9(2):167-77. PubMed ID: 23414467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ablation of insulin receptor substrates 1 and 2 suppresses
    Xu H; Lee MS; Tsai PY; Adler AS; Curry NL; Challa S; Freinkman E; Hitchcock DS; Copps KD; White MF; Bronson RT; Marcotrigiano M; Wu Y; Clish CB; Kalaany NY
    Proc Natl Acad Sci U S A; 2018 Apr; 115(16):4228-4233. PubMed ID: 29610318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.